

Prashanth & Neeraj

Chartered Accountants

INDEPENDENT AUDITOR'S REPORT

To
The Members
Spectrogen International Private Limited
Report on the Audit of Financial Statements

We have audited the accompanying financial statements of **Spectrogen International Private Limited** ("the Company"), which comprise the Balance Sheet as at 31st March, 2021, the Statement of Profit and Loss for the period then ended, and a summary of the significant accounting policies and other explanatory information. (Hereinafter referred to as "Financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014, of the state of affairs of the Company as at March 31, 2021, the Loss for the period ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information other than the Financial Statements and Auditors' Report Thereon ("Other Information"):

The Company's Board of Directors is responsible for the other information. The other information comprises the Management Discussion and Analysis and Board's Report including Annexures to Board's Report, but does not include the financial statements and our auditor's report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Prashanth & Neeraj

Chartered Accountants

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with relevant rules issued there under. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the company's financial reporting process.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

Prashanth & Neeraj

Chartered Accountants

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. This report does not include an annexure on the matters specified in paragraphs 3 and 4 of the Companies (Auditor's Report) Order, 2016, issued by the Central Government of India, in terms of sub-section (11) of section 143 of the Act, since in our opinion and according to the information and explanations given to us, said order is not applicable to the Company.
2. As required by section 143(3) of the Act, we further report that:
 - a) we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
 - b) in our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books;
 - c) the Balance Sheet, the Statement of Profit and Loss and the cash flow statement dealt with by this Report are in agreement with the books of account;
 - d) In our opinion, the aforesaid financial statements comply with the applicable Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules 2014.
 - e) On the basis of written representations received from the directors as on 31st March, 2021, and taken on record by the Board of Directors, none of the directors is disqualified as on 31st March 2021, from being appointed as a director in terms of Section 164(2) of the Act.


Prashanth & Neeraj

Chartered Accountants

- f) As the Company is a private Limited company, the provisions of section 197 read with Schedule V to the companies Act 2013, is not applicable
- g) As per Notification No. G.S.R. 583(E) dated 13th June 2017, we are not required to report on the adequacy of the internal financial controls of the company for the year ended March 31st 2021
- h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- i. The Company does not have any pending litigations which would impact its financial position
- ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
- iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

For Prashanth & Neeraj
Chartered Accountants
Firm Registration No.0170825


(Pilla Sai Prashanth)
Partner
Membership Number: 210719



UDIN: 22240716AAVHWY5324

Place: Hyderabad
Date:11-12-2021

SPECTROGEN INTERNATIONAL PRIVATE LIMITED**CIN - U24299TG2020PTC147109****Balance sheet as at March 31, 2021**

(All amounts are in Indian Rupees except share data and unless otherwise stated)

	Notes	As at March 31,2021
I. EQUITY AND LIABILITIES		
Shareholders' funds		
Share capital	2	10,00,000
Reserves and surplus	3	(56,168)
Share application money pending allotment		
Current liabilities		
Short-term borrowings	4	1,56,000
Other current liabilities	5	15,000
Total Equity and Liabilities		11,14,832
II. ASSETS		
Non Current Assets		
Deferred Tax Asset (net)		18,891
Current assets		
Short-term loans and advances	6	7,50,300
Cash and cash equivalents	7	3,45,641
Total Assets		11,14,832

Significant accounting policies and notes to accounts 1 to 16

The accompanying notes are an integral part of the financial statements.

As per our report of even date.

for Prashanth & Neeraj

Chartered accountants

Firm Registration No. 017082S

For and on behalf of the Board of Directors

of Spectrogen International Private Limited**Sd/-****(Pilla Sai Prashanth)**

Partner

Membership No. 240716

Sd/-**(Udaya Kiran Perla)**

Director

DIN:07313247

Sd/-**(Yamaka Santhi)**

Director

DIN:07820062

Place: Hyderabad

Date: 11.12.2021

SPECTROGEN INTERNATIONAL PRIVATE LIMITED**CIN - U24299TG2020PTC147109****Statement of Profit and Loss for the Period ended March 31, 2021**

(All amounts are in Indian Rupees except share data and unless otherwise stated)

	Notes	Period Ended March 31,2021
Income		
Revenue from operations		-
Other income		-
Total income		-
Expenses		
Operating Expenses		-
Finance costs	8	59
Depreciation and Amortization Expenses		-
Other expenses	9	75,000
Total expenses		75,059
Profit before tax		(75,059)
Tax expense		
Current tax		-
Deferred tax		(18,891)
Profit for the year		(56,168)
Earnings per equity share:		
Basic earnings per share		(2.07)
Diluted earnings per share		(2.07)
Nominal value per equity share		

Significant accounting policies and notes to accounts 1 to 16

The accompanying notes are an integral part of the financial statements.

As per our report of even date

for Prashanth & Neeraj

Chartered accountants

Firm Registration No. 017082S

For and on behalf of the Board of Directors

of Spectrogen International Private Limited

Sd/-
(Pilla Sai Prashanth)
Partner
Membership No. 240716

Sd/-
(Udaya Kiran Perla)
Director
DIN:07313247

Sd/-
(Yamaka Santhi)
Director
DIN:07820062

Place: Hyderabad

Date: 21.12.2021

SPECTROGEN INTERNATIONAL PRIVATE LIMITED

CIN - U24299TG2020PTC147109

Notes to financial statements

(All amounts are in Indian Rupees except share data and unless otherwise stated)

2.Share capital

	As at March 31, 2021
Authorized Share capital	
1,00,000 Equity Shares of par value of Rs.10/- each	10,00,000
	10,00,000
Issued, Subscribed and fully paid up shares	
1,00,000 Equity Shares of par value of Rs.10/- each	10,00,000
Total Issued, Subscribed and fully paid-up Share Capital	10,00,000

2.1 Reconciliation of number of shares outstanding and amount at the beginning and at the end of the year

	As at March 31, 2021
	Numbers
Number of shares at the beginning of the year	-
Add: Shares issued during the year	1,00,000
Number of shares at the end of the year	1,00,000

2.2 Details of shareholders holding more than 5% equity shares in the Company

Particulars	As at March 31, 2021	
	Numbers	% of Holding
Starus Pharmaceuticals Private Limited	40,000	40%
Srinivasa Reddy Devireddy	45,000	45%
Veerareddy	10,000	10%
Yamaka Santhi	5,000	5%
	1,00,000	100%

2.3 Terms/rights attached to equity shares

The Company has only one class of equity shares having par value of Rs.10/- each. Each holder of equity shares is entitled for one vote per share. Distribution of dividends and repayment of capital, if any, by the company, shall be subject to the provisions of applicable laws. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

3. Reserves & Surplus

	As at March 31, 2021
Surplus in Statement of Profit and Loss	
Balance at the beginning of the year	
Add: Profit/(loss) for the year	(56,168)
Balance at the end of the year	(56,168)

SPECTROGEN INTERNATIONAL PRIVATE LIMITED**CIN - U24299TG2020PTC147109****Notes to financial statements**

(All amounts are in Indian Rupees except share data and unless otherwise stated)

4. Short term borrowings

As at March 31, 2021	
Unsecured Loans	
Loans from Related Parties	
-From directors	1,56,000
Total	1,56,000

5. Other Current Liabilities

As at March 31, 2021	
Expenses Payable	15,000
Total	15,000

6. Short-term loans and advances.

As at March 31, 2021	
Advances for Purchase of Goods	5,50,000
Chit funds (Margadarshi Chits)	2,00,300
Total	7,50,300

7. Cash and cash equivalents

As at March 31, 2021	
Balance with banks:	
-in Current Accounts	3,45,641
Cash in Hand	-
Total	3,45,641

SPECTROGEN INTERNATIONAL PRIVATE LIMITED**CIN - U24299TG2020PTC147109****Notes to financial statements**

(All amounts are in Indian Rupees except share data and unless otherwise stated)

9. Finance Cost

	Period Ended March 31, 2021
Bank Charges	59
Total	59

10. Other expenses

	Period Ended March 31, 2021
Rates & Taxes	1,500
Preliminary Expenses	30,000
Promotional Expenses	28,500
Audit Fees	15,000
Total	75,000

Spectrogen International Private Limited

U24299TG2020PTC147109

Notes to financial statements

NOTE NO: 1 SIGNIFICANT ACCOUNTING POLICIES:

a) Corporate information

Spectrogen International Private Limited (the company) is a Private Limited company limited by shares incorporated in Telangana with Registrar of companies, Hyderabad to carry on the business of trading and manufacturing of Pharmaceutical Products and other allied activities relating to it.

b) Basis of Accounting :

- The financial statements have been prepared in accordance with Indian Generally Accepted Accounting Principles (GAAP) under the historical cost convention and in accordance with the applicable Accounting Standards as prescribed under Section 133 of the Companies Act, 2013 ('Act') read with Rule 7 of the Companies (Accounts) Rules, 2014, the provisions of the Companies Act, 2013 (to the extent notified) and the Companies Act, 1956 (to the extent applicable) and adopted consistently by the company.
- Accounting policies not specifically referred to otherwise are in consonance with prudent accounting principles.
- All revenues, expenses, assets and liabilities having material bearing on the financial statements are recognized on accrual basis, unless otherwise stated.

c) Use of Estimates:

The preparation of financial statements requires estimates and assumptions to be made that affect the reported amount of assets and liabilities on the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Difference between the actual results and estimates are recognized in the period in which the results are known/ materialized.

d) Fixed Assets:

- i) Fixed assets are stated at cost less accumulated depreciation. All costs, directly attributable to bringing the asset to the present condition for the intended use, are capitalised.
- ii) Assets under installation/construction, direct costs and related incidental expenses incurred on assets that are not ready for their intended use or not put to use as on the Balance Sheet date are stated as capital work in progress.

e) Depreciation:

Depreciation on fixed assets has been provided based on the useful lives as prescribed under Part C of the Schedule II of the Companies Act, 2013.

f) Taxation:

Current Tax:

Provision for current income tax is made as per the provisions of the Income Tax Act 1961.

Deferred Tax:

Deferred Tax is calculated at applicable statutory Income Tax rate and is recognised on timing differences between taxable income and accounting income that originated in one period and are capable of reversal in one or more subsequent periods.

g) Earnings per Share:

The Company reports Basic and Diluted earnings per share in accordance with AS-20 "Earnings per Share". The Basic earnings per share is computed by dividing the profit by the weighted average number of equity shares outstanding during the period. The Diluted earnings per share has been calculated by dividing the profit by the weighted average number of equity shares considered for deriving basic earnings per share and also the weighted average number of equity shares that could have been issued upon conversion of all dilutive potential equity shares.

h) Provisions, Contingent Liabilities and Assets:

The Company recognizes a provision when there is a present obligation as a result of a past event that probably requires outflow of resources, which can be reliably estimated. Disclosures for a contingent liability is made, without a provision in books, when there is an obligation that may, but probably will not, require outflow of resources. Contingent Assets are neither recognized nor disclosed.

8. Paise have been rounded off to the nearest rupee.

9. Auditors' Remuneration:

PARTICULARS	2020-21 Rupees
Audit Fee	15,000

TOTAL	20,000
	=====

10. The company doesn't have any of the suppliers of their being Micro, Small and Medium enterprises. Hence, the amounts due to Micro, Small and Medium enterprises outstanding as on 31st March, 2021 are nil.

11. Components of Deferred Tax Assets and Deferred Tax Liabilities:

PARTICULARS	31-03-2021 Deferred Tax (Asset)/Liability (Rupees)
Difference between book depreciation and tax depreciation	--
Other timing differences	(18,891)

Net Deferred Tax (Asset) / Liability	(18,891)
Less: Net Deferred Tax (Asset) / Liability at the beginning of the year	--

Net incremental (Asset) / liability (credited)/ charged to Profit and loss account	(18,891)
	=====

12. Number of shares used in computing earnings per share:

PARTICULARS	31-03-2021 (Face value of Rs.10/- each)
Number of shares considered as weighted average shares for calculation of Basic Earnings per Share	27,123
Add : Dilutive effect of potential shares	---
Number of shares considered as weighted average shares and potential shares outstanding for calculation of Diluted EPS	27,123

Spectrogen International Private Limited**U24299TG2020PTC147109****Notes to financial statements**

13. Related party transactions as per Accounting Standard-18 are as below:

i. Related parties and nature of relationship:

Relationship	Name of the Related party
Shareholders	Starus Pharmaceuticals Private Limited
	Srinivasa Reddy Devireddy
	Veerareddy
	Yamaka Santhi
Directors	Udaya Kiran Perla
	Yamaka Santhi

ii. Transactions with related parties:

Name of the Related party	Nature of Transaction	2020-21 Rupees
Starus Pharmaceuticals Private Limited	Share Capital	4,00,000
Yamaka Santhi	Share Capital	50,000
	Unsecured loan	56,000
Srinivasa Reddy Devireddy	Share Capital	4,50,000
Veera reddy	Share Capital	1,00,000
Udaya Kiran Perla	Unsecured loan	1,00,000

iii. Related parties outstanding balances:

Name of the Related party	Nature of Transaction	31-03-2021 Rupees
Starus Pharmaceuticals Private Limited	Share Capital	4,00,000
Yamaka Santhi	Share Capital	50,000
	Unsecured loan	56,000
Srinivasa Reddy Devireddy	Share Capital	4,50,000
Veerareddy	Share Capital	1,00,000
Udaya Kiran Perla	Unsecured loan	1,00,000

As per our report of even date
for **Prashanth & Neeraj**
Chartered Accountants
Firm Registration No.017082S

on behalf of the Board
for **Spectrogen International Private Limited**

(P. Sai Prashanth)
Partner
Membership No. 240716

(Uday Kiran Perla)
Director
DIN 07313247

(Yamaka Santhi)
Director
DIN 07820062

Place: Hyderabad

Date : 11-12-2021